» Articles » PMID: 9454612

Blastula-stage Stem Cells Can Differentiate into Dopaminergic and Serotonergic Neurons After Transplantation

Overview
Journal Exp Neurol
Specialty Neurology
Date 1998 Feb 10
PMID 9454612
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

In order to assess the potential of embryonic stem cells to undergo neuronal differentiation in vivo, totipotent stem cells from mouse blastocysts (D3 and E14TG2a; previously expanded in the presence of leukemia inhibitory factor) were transplanted, with or without retinoic acid pretreatment, into adult mouse brain, adult lesioned rat brain, and into the mouse kidney capsule. Intracerebral grafts survived in 61% of cyclosporine immunosuppressed rats and 100% of mouse hosts, exhibited variable size and morphology, and both intracerebral and kidney capsule grafts developed large numbers of cells exhibiting neuronal morphology and immunoreactivity for neurofilament, neuron-specific enolase, tyrosine hydroxylase (TH), 5-hydroxytryptamine (5-HT), and cells immunoreactive for glial fibrillary acidic protein. Though graft size and histology were variable, typical grafts of 5-10 mm3 contained 10-20,000 TH+ neurons, whereas dopamine-beta-hydroxylase+ cells were rare. Most grafts also included nonneuronal regions. In intracerebral grafts, large numbers of astrocytes immunoreactive for glial fibrillary acidic protein were present. Both TH+ and 5-HT+ axons from intracerebral grafts grew into regions of the dopamine-lesioned host striatum. TH+ axons grew preferentially into striatal gray matter, while 5-HT+ axons showed no white/gray matter preference. These findings demonstrate that transplantation to the brain or kidney capsule can induce a significant fraction of totipotent embryonic stem cells to become putative dopaminergic or serotonergic neurons and that when transplanted to the brain these neurons are capable of innervating the adult host striatum.

Citing Articles

Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases.

Ore A, Angelastro J, Giulivi C Brain Sci. 2024; 14(9).

PMID: 39335395 PMC: 11429837. DOI: 10.3390/brainsci14090899.


The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson's disease.

Xiao Z, Lei T, Liu Y, Yang Y, Bi W, Du H Stem Cell Res Ther. 2021; 12(1):5.

PMID: 33407864 PMC: 7789713. DOI: 10.1186/s13287-020-01957-4.


Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients.

Osborn T, Hallett P, Schumacher J, Isacson O Front Cell Neurosci. 2020; 14:58.

PMID: 32317934 PMC: 7147334. DOI: 10.3389/fncel.2020.00058.


The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders.

Smith D, He M, Zhang C, Zheng J Prog Neurobiol. 2016; 157:212-229.

PMID: 26844759 PMC: 5848468. DOI: 10.1016/j.pneurobio.2016.01.006.


Oligodendrocyte Precursor Cells in Spinal Cord Injury: A Review and Update.

Li N, Leung G Biomed Res Int. 2015; 2015:235195.

PMID: 26491661 PMC: 4600489. DOI: 10.1155/2015/235195.